Alumis Inc. Gains Analysts’ Attention with Promising Psoriasis Treatment and Attractive Valuation
Guggenheim Partners has commenced coverage on Alumis Inc. (NASDAQ ), a clinical-stage biopharmaceutical firm focused on developing oral therapies for ...